Recent advances in oncolytic virus-based cancer therapy.
Administration of oncolytic viruses (OVs) is an emerging anticancer strategy that exploits the lytic nature of viral replication to enhance the killing of malignant cells. OVs can be used as tools to directly induce cancer cell death and to trigger local and/or systemic immune responses to metastatic cancer in vivo. The effectiveness of OV therapy was initially highlighted by the clinical use of the genetically modified herpes virus, talimogene laherparepvec, for melanoma therapy. A number of OVs are now being evaluated as potential treatments for cancer in clinical trials. In spite of being engineered to specifically target tumor cells, the safety and off-target effects of OV therapy are a concern. The potential safety concerns of OVs are highlighted by current clinical trial criteria, which exclude individuals harbouring other viral infections and people who are immunocompromised. Despite the potential for adverse effects, clinical trials to date revealed relatively minimal adverse immune-related effects, such as fever. With advances in our understanding of virus replication cycles, several novel OVs have emerged. Reverse genetic systems have facilitated the insertion of anticancer genes into a range of OVs to further enhance their tumor-killing capacity. In this review, we highlight the recent advances in OV therapy for a range of human cancers in in vitro and in in vivo animal studies. We further discuss the future of OVs as a therapeutic strategy for a range of life-threatening cancers.
['Fu|Luo-Qin|LQ|', 'Wang|Shi-Bing|SB|', 'Cai|Mao-Hua|MH|', 'Wang|Xue-Jun|XJ|', 'Chen|Jin-Yang|JY|', 'Tong|Xiang-Min|XM|', 'Chen|Xiao-Yi|XY|', 'Mou|Xiao-Zhou|XZ|']
D000818:Animals D002986:Clinical Trials as Topic D004195:Disease Models, Animal D006801:Humans D008545:Melanoma D009369:Neoplasms D050130:Oncolytic Virotherapy D050504:Oncolytic Viruses D059386:Reverse Genetics D014779:Virus Replication
Cancer Viral replication Antitumor immunity Oncolytic virus Virotherapy